Overproduction of altered VLDL in an insulin-resistance rat model: Influence of SREBP-1c and PPAR-α

Clinica e Investigacion en Arteriosclerosis

Volumn 27, Issue 4, 2015, Pages 167-174

  Lucero, Diego ^a   Miksztowicz, Verónica ^a   Macri, Vanesa ^a   López, Gustavo H ^b   Friedman, Silvia ^a   Berg, Gabriela ^a   Zago, Valeria ^a   Schreier, Laura ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b National Southern University   (Argentina)

Author keywords

Insulin resistance; Large very low density lipoprotein; Peroxisome proliferator activated receptor ; Sterol regulatory element binding protein 1c; Sucrose rich diet

Indexed keywords

FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; SUCROSE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID ANALYSIS; LIPID LIVER LEVEL; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT; ANIMAL; DISEASE MODEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPID METABOLISM; LIVER; METABOLISM; PHYSIOLOGY; WISTAR RAT;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; FATTY ACIDS, NONESTERIFIED; INSULIN; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LIPID METABOLISM; LIPOPROTEINS, VLDL; LIVER; MALE; PPAR ALPHA; RATS; RATS, WISTAR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIGLYCERIDES;

EID: 84952874590     PISSN: 02149168     EISSN: 15781879     Source Type: Journal    
DOI: 10.1016/j.arteri.2014.11.002     Document Type: Article

References (31)

1. Kassi E., Pervanidou P., Kaltsas G., Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med 2011, 9:48.
2. Zago V., Lucero D., Macri E.V., Cacciagiú L., Gamba C.A., Miksztowicz V., et al. Circulating very-low-density lipoprotein characteristics resulting from fatty liver in an insulin resistance rat model. Ann Nutr Metab 2010, 56:198-206.
3. Lucero D., Zago V., López G.H., Cacciagiú L., López G.I., Wikinski R., et al. Predominance of large VLDL particles in metabolic syndrome, detected by size exclusion liquid chromatography. Clin Biochem 2012, 45(4-5):293-297.
4. Eberlé D., Hegarty B., Bossard P., Ferré P., Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 2004, 86:839-848.
5. Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999, 20:649-688.
6. Pettinelli P., Obregón A.M., Videla L.A. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease. Nutr Hosp 2011, 26:441-450.
7. Rossi A.S., Oliva M.E., Ferreira M.R., Chicco A., Lombardo Y.B. Dietary chia seed induced changes in hepatic transcription factors and their target lipogenic and oxidative enzyme activities in dyslipidaemic insulin-resistant rats. Br J Nutr 2013, 109:1617-1627.
8. Zhang C., Chen X., Zhu R.M., Zhang Y., Yu T., Wang H., et al. Endoplasmic reticulum stress is involved in hepatic SREBP-1c activation and lipid accumulation in fructose-fed mice. Toxicol Lett 2012, 212:229-240.
9. Cintra D.E., Ropelle E.R., Vitto M.F., Luciano T.F., Souza D.R., Engelmann J., et al. Reversion of hepatic steatosis by exercise training in obese mice: the role of sterol regulatory element-binding protein-1c. Life Sci 2012, 91(11-12):395-401.
10. Hein G.J., Bernasconi A.M., Montanaro M.A., Pellon-Maison M., Finarelli G., Chicco A., et al. Nuclear receptors and hepatic lipidogenic enzyme response to a dyslipidemic sucrose-rich diet and its reversal by fish oil n-3 polyunsaturated fatty acids. Am J Physiol Endocrinol Metab 2010, 298:E429-E439.
11. Gutman R.A., Basílico M.Z., Bernal C.A., Chicco A., Lombardo Y.B. Long-term hypertriglyceridemia and glucose intolerance in rats fed chronically an isocaloric sucrose-rich diet. Metabolism 1987, 36:1013-1020.
12. Guide for the Care and Use of Laboratory Animals, National Institutes of Health. Publication No. 85-23, revised 1996.
13. Schumaker V.N., Puppione D.L. Sequential flotation ultracentrifugation. Methods Enzymol 1986, 128:155-170.
14. Sasse J., Gallagher S.R. Staining proteins in gels. Curr Protoc Mol Biol 2003, [chapter 10: unit 10.6].
15. Bartlett G.R. Phosphorus assay column chromatography. J Biol Chem 1975, 193:265-275.
16. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
17. Folch J., Lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957, 226:497-509.
18. Fruchart J.C. Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 2009, 205:1-8.
19. Aguilera A.A., Díaz G.H., Barcelata M.L., Guerrero O.A., Ros R.M. Effects of fish oil on hypertension, plasma lipids, and tumor necrosis factor-alpha in rats with sucrose-induced metabolic syndrome. J Nutr Biochem 2004, 15:350-357.
20. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005, 115:1343-1351.
21. Duvnjak L., Duvnjak M. The metabolic syndrome - an ongoing story. J Physiol Pharmacol 2009, 60(Suppl 7):19-24.
22. Kotronen A., Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:27-38.
23. Mead J.R., Irvine S.A., Ramji D.P. Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med (Berl) 2002, 80:753-769.
24. Chan D.C., Watts G.F., Redgrave T.G., Mori T.A., Barrett P.H. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism 2002, 51:1041-1046.
25. Vergès B. Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes. Atherosclerosis 2010, 211:353-360.
26. Adiels M., Taskinen M.R., Borén J. Fatty liver, insulin resistance, and dyslipidemia. Curr Diab Rep 2008, 8:60-64.
27. Adiels M., Borén J., Caslake M.J., Stewart P., Soro A., Westerbacka J., et al. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2005, 25:1697-1703.
28. Zago V., Gorzalczany S., Lucero D., Taira C., Schreier L. Role of HDL in neutralizing the VLDL effect on endothelial dysfunction. Microvasc Res 2013, 89:153-158.
29. Karasawa T., Takahashi A., Saito R., Sekiya M., Igarashi M., Iwasaki H., et al. Sterol regulatory element-binding protein-1 determines plasma remnant lipoproteins and accelerates atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2011, 31:1788-1795.
30. Tontonoz P., Hu E., Graves R.A., Budavari A.I., Spiegelman B.M. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994, 8:1224-1234.
31. Yu S., Matsusue K., Kashireddy P., Cao W.Q., Yeldandi V., Yeldandi A.V., et al. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J Biol Chem 2003, 278:498-505.